<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03701568</url>
  </required_header>
  <id_info>
    <org_study_id>MT-1621-101</org_study_id>
    <nct_id>NCT03701568</nct_id>
  </id_info>
  <brief_title>A RETROspective Study of Patients With TK2d</brief_title>
  <acronym>RETRO</acronym>
  <official_title>A RETROspective Study of the Combination of Pyrimidine Nucleos(t)Ides in Patients With Thymidine Kinase 2 Deficiency (TK2)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Modis Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Modis Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a medical chart review study to collect information for patients who have been taking
      pyrimidine nucleosides for treatment of TK2 deficiency. Information from the time of onset of
      symptoms will be collected to describe the pre treatment course of TK2 deficiency.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Data to be collected from the time of onset of symptoms related to TK2 deficiency includes
      medical conditions and/or adverse events (AEs); these should include relationship to TK2
      disease and/or pyrimidine nucleosides, as appropriate, as well as date of onset and severity,
      when available. When available, test reports may be obtained as well as available research
      biological samples (eg, blood or tissue samples that may be tested for biomarkers of disease
      and/or effects of medications to treat the mitochondrial disease).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 19, 2018</start_date>
  <completion_date type="Actual">May 31, 2019</completion_date>
  <primary_completion_date type="Actual">April 30, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Diagnosis</measure>
    <time_frame>3 months</time_frame>
    <description>genetic testing (previously conducted)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical course</measure>
    <time_frame>3 months</time_frame>
    <description>BMI (height in inches and weight in kg will be combined to report BMI in kg/m^2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical course</measure>
    <time_frame>3 months</time_frame>
    <description>achievement, loss, or regaining of developmental motor milestones</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Motor function and ambulatory assessments</measure>
    <time_frame>3 months</time_frame>
    <description>Change in 6-minute walk test [6MWT] distance (in meters)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Motor function and ambulatory assessments</measure>
    <time_frame>3 months</time_frame>
    <description>Motor Function Measure [MFM] 20 or MFM 32</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Motor function and ambulatory assessments</measure>
    <time_frame>3 months</time_frame>
    <description>Egen Klassifikation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Motor function and ambulatory assessments</measure>
    <time_frame>3 months</time_frame>
    <description>North Star Ambulatory Assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Motor function and ambulatory assessments</measure>
    <time_frame>3 months</time_frame>
    <description>Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders [CHOP INTEND]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Motor function and ambulatory assessments</measure>
    <time_frame>3 months</time_frame>
    <description>Hammersmith Functional Motor Scale—Expanded [HFMSE]</description>
  </secondary_outcome>
  <enrollment type="Actual">38</enrollment>
  <condition>Thymidine Kinase 2 (TK2)</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dC/dT</intervention_name>
    <description>Collection of retrospective data from TK2 patients previously treated with dC/dT</description>
    <other_name>deoxycytidine/deoxythymidine</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      When available, test reports maybe obtained (eg, reports from genetic testing, muscle biopsy)
      as well as available research biological samples (eg, blood or tissue samples that may be
      tested for biomarkers of disease and/or effects of medications to treat the mitochondrial
      disease).
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with TK2 deficiency who have received treatment with pyrimidine nucleosides
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Signed informed consent by the patient or parent(s)/legally authorized representative
             (LAR) and/or assent by the patient (when applicable), unless the associated
             institutional review board (IRB) or ethics committee (EC) provides an appropriate
             consent waiver

          2. Confirmed genetic mutation in the TK2 gene

          3. Availability of medical records for each patient from the time of onset of symptoms

          4. Patient has taken pyrimidine nucleos(t)ides (dCMP/dTMP and/or dC/dT) as substrate
             enhancement therapy for TK2 deficiency

          5. Most recent patient visit at which efficacy and/or safety parameters were collected
             occurred between 01 June 2018 and 15 December 2018

        Exclusion Criteria:

        1. Presence of other genetic disease or polygenic disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rambam Hospital</name>
      <address>
        <city>Haifa</city>
        <zip>3109601</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wolfson Medical Center</name>
      <address>
        <city>Holon</city>
        <zip>5822012</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Western Galilee Hospital</name>
      <address>
        <city>Nahariya</city>
        <zip>89 כביש</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sant Joan de Déu Hospital</name>
      <address>
        <city>Barcelona</city>
        <zip>08950</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocio</name>
      <address>
        <city>Seville</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>September 27, 2018</study_first_submitted>
  <study_first_submitted_qc>October 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 10, 2018</study_first_posted>
  <last_update_submitted>June 9, 2019</last_update_submitted>
  <last_update_submitted_qc>June 9, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>myopathy, muscle weakness, hypotonia, dysphagia, ptosis</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

